Alcon Inc.
ALC · New York Stock Exchange · USD
75,14USD
+0,20 (+0,27 %)Stand 9. Nov., 21:00
Nachbörslich75,140,00 (0,00 %)17:41 ET
Kennzahlen
- Eröffnung
- 74,62
- Vortag
- 74,94
- Tagesspanne
- 74,28 – 75,49
- 52 Wochen
- 61,84 – 87,64
- Volumen
- 2,81 Mio.
- Ø Volumen
- 1,89 Mio.
- Börsenwert
- 36,32 Mrd. $
- KGV
- 57,8
- Gewinn je Aktie (TTM)
- 1,30
- Dividendenrendite
- 0,5 %
- Beta
- 0,7
- Nächste Zahlen
- 10. Nov. 2026
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 10,4 Mrd. | 9,91 Mrd. | 9,46 Mrd. | 8,72 Mrd. | 8,29 Mrd. |
| Herstellungskosten | 4,66 Mrd. | 4,4 Mrd. | 4,21 Mrd. | 3,97 Mrd. | 3,64 Mrd. |
| Bruttogewinn | 5,75 Mrd. | 5,51 Mrd. | 5,25 Mrd. | 4,75 Mrd. | 4,65 Mrd. |
| Forschung und Entwicklung | 990 Mio. | 876 Mio. | 859 Mio. | 702 Mio. | 842 Mio. |
| Vertrieb und Verwaltung | 3,45 Mrd. | 3,25 Mrd. | 3,21 Mrd. | 3,07 Mrd. | 3,08 Mrd. |
| Operatives Ergebnis | 1,36 Mrd. | 1,41 Mrd. | 1,04 Mrd. | 672 Mio. | 580 Mio. |
| EBITDA | 2,5 Mrd. | 2,68 Mrd. | 2,24 Mrd. | 1,74 Mrd. | 1,76 Mrd. |
| Nettogewinn | 980 Mio. | 1,02 Mrd. | 974 Mio. | 335 Mio. | 376 Mio. |
| Gewinn je Aktie (verwässert) | 1,98 | 2,05 | 1,96 | 0,68 | 0,76 |
Umsatz nach Segment
Regionen · FY 2025
- International Geographic Areas5,66 Mrd. $35,43 %+6,33 %
- UNITED STATES4,66 Mrd. $29,14 %+3,24 %
- Other Countries4,41 Mrd. $27,61 %+6,78 %
- JAPAN609 Mio. $3,81 %+9,93 %
- CHINA570 Mio. $3,57 %+1,79 %
- SWITZERLAND71 Mio. $0,44 %−10,13 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 57,8
- Kurs-Umsatz-Verhältnis
- 3,4
- Kurs-Buchwert-Verhältnis
- 1,7
- PEG
- -1,4
- Bruttomarge
- 56,5 %
- Operative Marge
- 9,9 %
- Nettomarge
- 5,9 %
- Verschuldungsgrad
- 0,2
- EV/EBITDA
- 14,5
- Eigenkapitalrendite
- 2,9 %
- Kapitalrendite (ROIC)
- 3,2 %
- Free-Cashflow-Rendite
- 4,6 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 55,2 % | 55,6 % | 55,5 % | 54,5 % | 56,1 % |
| Operative Marge | 13,1 % | 14,3 % | 11,0 % | 7,7 % | 7,0 % |
| Nettomarge | 9,4 % | 10,3 % | 10,3 % | 3,8 % | 4,5 % |
| KGV | 39,6 | 41,2 | 39,5 | 100,8 | 113,1 |
| Kurs-Umsatz-Verhältnis | 3,8 | 4,2 | 4,1 | 3,9 | 5,1 |
| Kurs-Buchwert-Verhältnis | 1,8 | 1,9 | 1,9 | 1,7 | 2,2 |
| Verschuldungsgrad | 0,2 | 0,2 | 0,2 | 0,3 | 0,2 |
| Liquidität 3. Grades | 2,1 | 2,8 | 2,4 | 1,9 | 2,2 |
| Dividendenrendite | 0,4 % | 0,3 % | 0,3 % | 0,3 % | 0,1 % |
| Unternehmenswert | 42,73 Mrd. | 45,43 Mrd. | 42,55 Mrd. | 37,77 Mrd. | 45,59 Mrd. |
| EV/EBITDA | 17,1 | 17,0 | 19,0 | 21,7 | 25,9 |
| Eigenkapitalrendite | 4,4 % | 4,7 % | 4,7 % | 1,7 % | 2,0 % |
| Kapitalrendite (ROIC) | 3,9 % | 4,1 % | 3,8 % | 1,8 % | 2,0 % |
| Free-Cashflow-Rendite | 4,1 % | 3,4 % | 1,4 % | 1,4 % | 0,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +4,9 % | +4,8 % | +8,5 % | +5,1 % | +21,3 % |
| Bruttogewinn | +4,2 % | +5,1 % | +10,5 % | +2,1 % | +58,2 % |
| Operatives Ergebnis | −3,8 % | +36,0 % | +54,6 % | +15,9 % | +220,3 % |
| Nettogewinn | −3,7 % | +4,5 % | +190,7 % | −10,9 % | +170,8 % |
| Gewinn je Aktie | −3,4 % | +4,6 % | +188,2 % | −10,5 % | +169,7 % |
| Freier Cashflow | +14,3 % | +162,0 % | +13,8 % | +186,1 % | −35,5 % |
| Dividende je Aktie | +27,6 % | +11,8 % | +12,0 % | +90,3 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 14Kaufen
- 10Halten
- 2Verkaufen
- 0Stark verkaufen
Kursziel
77,22
Durchschnitt · +2,77 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 11,1 Mrd. | 11,75 Mrd. | 12,45 Mrd. |
| Umsatz (Tief – Hoch) | 11,05 Mrd. – 11,17 Mrd. | 11,67 Mrd. – 11,84 Mrd. | 11,96 Mrd. – 12,86 Mrd. |
| Gewinn je Aktie (Ø) | 3,51 | 3,96 | 4,48 |
| Gewinn je Aktie (Tief – Hoch) | 3,42 – 3,54 | 3,78 – 4,12 | 3,06 – 5,38 |
| Analysten | 15 | 16 | 15 |
Letzte Änderungen
- Needham2. Nov. 2026Buy
- Keybanc27. Okt. 2026Overweight
- Needham21. Okt. 2026Buy
- BTIG12. Okt. 2026Buy
- Jefferies22. Sept. 2026Buy
- Needham15. Sept. 2026Buy
- Mizuho12. Aug. 2026Outperform
- JP Morgan12. Aug. 2026Neutral
Quartalszahlen
Nächste Zahlen: 10. Nov. 2026| Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,77 | 0,80 | 0,79 | 0,77 | 0,71 | 0,76 | 0,70 | 0,72 |
| Gewinn je Aktie · Tatsächlich | 0,84 | 0,85 | 0,78 | 0,79 | 0,76 | 0,73 | 0,72 | 0,81 |
| Abweichung | +9,09 % | +6,25 % | −1,27 % | +2,60 % | +7,04 % | −3,95 % | +2,86 % | +12,50 % |
| Umsatz · Tatsächlich | 2,79 Mrd. | 2,65 Mrd. | 2,64 Mrd. | 2,61 Mrd. | 2,6 Mrd. | 2,47 Mrd. | 2,5 Mrd. | 2,45 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 6. Mai 2026 | 7. Mai 2026 | 0,36 |
| 14. Mai 2025 | 15. Mai 2025 | 0,33 |
| 14. Mai 2024 | 16. Mai 2024 | 0,26 |
| 10. Mai 2023 | 12. Mai 2023 | 0,24 |
| 3. Mai 2022 | 5. Mai 2022 | 0,21 |
| 4. Mai 2021 | 6. Mai 2021 | 0,10 |
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 49,42 %
- Investoren mit 13F-Meldung
- 671
Größte Investoren
- VANGUARD CAPITAL MANAGEMENT LLC3,03 %14,75 Mio.
- BANK OF NEW YORK MELLON CORP2,68 %13,06 Mio.
- NORGES BANK2,26 %10,98 Mio.
- INVESCO LTD.2,13 %10,38 Mio.
- AKO CAPITAL LLP1,99 %9,68 Mio.
- ARISTOTLE CAPITAL MANAGEMENT, LLC1,88 %9,15 Mio.
- ZURCHER KANTONALBANK (ZURICH CANTONALBANK)1,63 %7,92 Mio.
- FMR LLC1,57 %7,66 Mio.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Führung
- David J. EndicottChief Executive Officer & Director
- Kimberly MartinSenior VP and Chief HR & Corporate Communications
- Daniel CravensVice President of Investor Relations
- Laurent AttiasSenior VP of Corporate Strategy, Business Development and Licensing (BD&L), M&A
- Leon Sergio Duplan FraustroSenior Vice President & President of Americas
- Royce R. BedwardSenior Vice President, General Counsel & Corporate Secretary
- CEO
- David J. Endicott
- Mitarbeitende
- 25.000
- Hauptsitz
- Geneva, GE, CH
- Sektor
- Healthcare
- Branche
- Medical - Specialties
- Börsengang
- 9. Apr. 2019
- Website
- alcon.com
Nachrichten
- Business Wire · 6. Nov., 8:42Algoma Central Corporation Announces Closing of Over-Allotment Option of Additional Debentures
- Business Wire · 6. Nov., 7:00Algoma Central Corporation Reports Financial Results for the 2026 Third Quarter
- Zacks Investment Research · 5. Nov., 10:16Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Zacks Investment Research · 5. Nov., 8:51Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
- Seeking Alpha · 4. Nov., 2:35Higher Margins, Better ROIC And Capable Management Define Pershing Square's Q3 2026 Portfolio
- Seeking Alpha · 21. Okt., 11:46Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In Eyecare
- Business Wire · 20. Okt., 16:35Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
- GlobeNewsWire · 20. Okt., 16:31Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures
- Business Wire · 16. Okt., 16:38FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
- Business Wire · 16. Okt., 15:57FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.